IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Analysis of IL-17E using IL-17E monoclonal antibody. Mouse testis lysate probed with IL-17E antibody at 2 ug/mL.

Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - Immunohistochemistry (IHC) staining of IL-17E/IL-25 was performed in a tissue microarray consisting of 74 CRC tumor tissues and adjacent colon tissues (left). Statistical analysis of IL-17E/IL-25 staining in adjacent specimens and CRC specimens (right). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953/) licensed under a CC-BY license.

Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Tissue section of mouse liver using IL17E/IL25 antibody clone 68C1039.2 at 1:150. The antibody generated a diffused cytoplasmic staining in the hepatocytes with a very strong signal in the sinusoidal endothelial cells.

Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Tissue section of mouse kidney using IL17E/IL25 antibody clone 68C1039.2 at 1:150. The antibody generated a diffused cytoplasmic staining in the tubular and ductal epithelia cells, and a strong positivity in the inter-tubular/ductal blood vessels.

Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Adrenal cortex, Human

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p 6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p 6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p 6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Mouse liver lysates probed with IL-17E/IL-25 Antibody at dilution 1:1000 in 1xTBST. Image from a verified customer review.

• Reactivity: Hu, Mu
• Applications: WB, ICC/IF, IHC
• Clone: 68C1039.2
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

IL-17E/IL-25 Antibody (68C1039.2) - BSA Free Summary

• Description: Novus Biologicals Mouse IL-17E/IL-25 Antibody (68C1039.2) - BSA Free (NB100-56541) is a monoclonal antibody validated for use in IHC, WB and ICC/IF. Anti-IL-17E/IL-25 Antibody: Cited in 5 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Amino acids 115-132 of human IL-17E (isoform CRA_a) were used as immunogen for this antibody.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IL25
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence reported in scientific literature (PMID 35359953)
  • Immunohistochemistry 1:100 - 1:500
  • Immunohistochemistry-Paraffin reported in scientific literature (Terrier B et al)
  • Western Blot 1:100 - 1:250
• Application Notes: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Theoretical MW: 20 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  IL-17E/IL-25 Overexpression Lysate

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Protein G purified

Alternate Names for IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

• IL17E
• IL-17E
• IL25
• IL-25
• interleukin 25
• Interleukin-17E
• interleukin-25

Background

A number of cytokines belonging to the interleukin (IL)-17 family have been identified, termed IL-17A-F. IL-17 is a potent proinflammatory cytokine that plays roles in a number of diseases including rheumatoid arthritis, multiple sclerosis, and promotion of tumor growth. IL-17E, C, and B are able to induce proinflammatory responses. However, they do not bind to the IL-17 receptor suggesting that an additional IL-17R related receptor may exist. Receptors for IL-17B and IL-17E have been independently isolated by Shi, et al and Lee, et al. and have been designated as EV127 (in mouse) and IL-17Rh1 (in human), respectively. IL-17E, also called IL-25, induces activation of NF-kB pathway and like IL-17 also induces production of IL-8.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-17E/IL-25 Antibody (NB100-56541)(7)

Publications using NB100-56541

• Kubo F, Ariestanti DM, Oki S et al. Loss of the adhesion G-protein coupled receptor ADGRF5 in mice induces airway inflammation and the expression of CCL2 in lung endothelial cells Respir. Res. 2019-01-17 [PMID: 30654796] (WB, Mouse)
• Liu Y, Sun X, Zhao X et al. Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease Pathol Res Pract 2018-04-19 [PMID: 29548809] (Human)
  
  Details:
  Citation using the Biotin form of this antibody.
• Liu Y, Zhao X, Sun X et al. Expression of IL-17A, E, and F and their receptors in human prostatic cancer: Comparison with benign prostatic hyperplasia. Prostate. 2015-12-01 [PMID: 26356122] (Human)
  
  Details:
  This citation used the Biotin version of this antibody.
• Terrier B, Bieche I, Maisonobe T et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood. 2010-11-01 [PMID: 20729468] (IHC-P)
  
  Details:
  IL-17E (IMG-323A). IHC (paraffin): Nerve tissue from patients with Churg-Strauss syndrome (CSS) or miscroscopic polyangiitis (MPA), Fig 5.
• Yi H Intestinal tuft cells in IBS patients: Relationship to mucosal IgE-expressing mast cells Thesis Jul 13 1905 (IHC)
• Yi H Intestinal tuft cells in IBS patients: Relationship to mucosal IgE-expressing mast cells Thesis 1905-07-13 (IF/IHC)
• Liu J, Qian B, Zhou L et al. IL25 Enhanced Colitis-Associated Tumorigenesis in Mice by Upregulating Transcription Factor GLI1 Frontiers in Immunology 2022-03-14 [PMID: 35359953] (ICC/IF, IF/IHC, Human, Mouse)

Review for IL-17E/IL-25 Antibody (NB100-56541) (1)

Average Rating: 4

(Based on 1 review)

We have 1 review tested in 1 species: Mouse.

reviewed by: Kamal Baral WB Mouse 10/21/2025

Summary

• Application: Western Blot
• Sample Tested: mouse liver lysate
• Species: Mouse
• Lot: CKCX03-12

FAQs for IL-17E/IL-25 Antibody (NB100-56541). (Showing 1 - 2 of 2 FAQs).

1. Are the following monoclonals purified from ascites or from tissue culture supernatant? NB100-56541, NB100-56705, NB600-1298, NB100-56534, NB100-56505, NBP2-24873, NB600-1107, NBP2-24917, NB100-56524, NB100-56712
   • These antibodies are all purified from tissue culture supernatant.
2. Would you be able to tell me if this Ab has neutralizing capabilities? Has it been tested?
   • This antibody has only been validated in Western blot and IHC on paraffin-embedded tissues. It has not been tested for its neutralizing capabilities.

Bioinformatics

• Gene Symbol: IL25
• Entrez:
  • 64806(Human)
  • 140806(Mouse)
• Uniprot:
  • Q9H293()